← Home
The Proof · August 4, 2026 · 1h 53m

Superagers, statins, the latest cholesterol pill and the truth about heart disease risk

Dr. Terry Simpson returns to The Proof for a wide-ranging conversation on heart disease prevention and healthy ageing. He explains why lifestyle choices matter more than genetics for maintaining a sharp brain as we age, and unpacks how PCSK9 inhibitors work by framing plaque buildup as a geological process. The discussion also covers gene editing for cholesterol, functional cures for type 1 diabetes, the lean mass hyperresponder debate, and new 2026 guidelines that recommend testing Lp(a) once. Along the way, Simpson and host Simon Hill air frustrations about misinformation outrunning careful science.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Canon

Simpson emphasizes that daily habits like diet, exercise, and cognitive engagement influence brain health more than genetic predisposition.
Rates of colorectal cancer are increasing in people under 50, prompting calls for greater awareness and earlier screening.
New guidelines advise measuring Lp(a) once in a lifetime because elevated levels are genetically determined and a powerful independent risk factor.

Novel

Gene Editing for Cholesterol and Type 1 Diabetes Cures
Emerging gene editing approaches aim to provide permanent cholesterol reduction and functional cures for type 1 diabetes.

Highlights

PCSK9 Inhibitors and the Geology of Plaque
PCSK9 inhibitors lower LDL cholesterol by enhancing the liver's ability to clear it, and Simpson reframes arterial plaque as geology, not plumbing.
The Lean Mass Hyperresponder Debate and Keto-CTA Re-Analysis
A controversial paper on cholesterol responses to ketogenic diets is re-examined, shedding new light on the lean mass hyperresponder phenomenon.

Misc

Simpson and Hill vent about how misinformation spreads faster than the careful, evidence-based answer.
Was this useful?